



## **VGX Pharmaceuticals closes investment by the Korea Development Bank**

**Blue Bell, PA – September 19, 2007 –**

VGX Pharmaceuticals announced today that it has closed a \$4 million common stock investment by the Korea Development Bank.

The Company intends to use the proceeds for the development of its drug candidates and for its working capital needs. The Company currently has two candidates in Phase II clinical trials and expects several preclinical candidates to enter Phase I trials in the coming months.

“The investment by KDB represents a significant outside validation of all the hard work and progress that our Company has made. We are truly delighted that KDB has become an investor in our Company and we hope that this is just the beginning of a long and fruitful relationship between us. While we were not actively seeking financing at this time, having an investor of KDB’s stature and influence was an opportunity that we could not afford to miss,” said Dr. J. Joseph Kim, CEO of VGX Pharmaceuticals.

**Cautionary Factors That May Affect Future Results** - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on [www.vgxp.com](http://www.vgxp.com) as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

### **About VGX Pharmaceuticals**

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, and PENNVAX™-B, a DNA vaccine for preventing HIV infection, which is in Phase I clinical trials. In addition, VGX is planning to initiate Phase I clinical studies for VGX-1027, its lead compound for inflammatory diseases. VGX's research pipeline includes a new generation of SynCon™ DNA vaccines and therapeutics as well as the CELLECTRA™ electroporator, a patented DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at [www.vgxp.com](http://www.vgxp.com).

### **About Korea Development Bank**

Korea Development Bank is a state-owned bank founded in 1954 in accordance with The Korea Development Bank Act for the purpose of financing and managing major industrial projects to expedite industrial development and enhance the national economy. KDB enjoys a special status as Korea's sole developmental finance institution. The bank acts as an intermediary to ensure that capital is channeled to strategic and often under-served sectors. It also plays a critical role in the country's reform efforts by providing advisory services and capital to facilitate corporate restructuring. More information about KDB can be found at [www.kdb.co.kr](http://www.kdb.co.kr).

### **Company Contact:**

Kevin W. Rassas

Senior Vice President

Tel. 267.440.4208

Fax 267.440.4242

E-mail: [Rassas@vgxp.com](mailto:Rassas@vgxp.com)

[www.vgxp.com](http://www.vgxp.com)